Dr. Steven Nissen to Chair Steering Committee for Landmark ApoA-I Trial
TSX Exchange Symbol: RVX
CALGARY, Oct. 7 /CNW/ - Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) is pleased to announce the formation of the Steering
Committee for the RVX-208 Phase 2b clinical trial assessing atherosclerosis by
IVUS (Intravascular Ultrasound). This is a study in Acute Coronary Syndrome
patients expected to start in 2009.
"We are honored to have an experienced and highly esteemed group of
internationally recognized cardiologists to lead this important IVUS
atherosclerosis study," said Mr. Donald J. McCaffrey, President and CEO of
Resverlogix. "ApoA-IMilano infusions have previously been shown to be the most
efficient means to reduce atherosclerosis, we will now test the hypothesis
that a permanent endogenous ApoA-I increase by oral administration of RVX-208
has the same capacity".
Appointed members of the Phase 2b IVUS Steering Committee include:
Chairman: Dr. Steven Nissen, M.D., Chairman of the Department of
Cardiovascular Medicine located on the main campus of Cleveland
Principal Investigator: Dr. Stephen Nicholls, M.B.B.S, Ph.D., Medical
Director of Intravascular Ultrasound and Angiography Core
Laboratories at Cleveland Clinic and Clinical Director of the
Cleveland Clinic Center for Cardiovascular Diagnostics and
Dr. Christie M. Ballantyne, M.D., Associate Chief and Professor,
Section of Atherosclerosis and Lipoprotein Research, Baylor College
of Medicine, Houston, Texas.
Dr. John J.P. Kastelein, M.D., Ph.D., Professor of Medicine and
Chairman of the Department of Vascular Medicine at the Academic
Medical Centre (AMC) of the University of Amsterdam, where he holds
the Strategic Chair of Genetics of Cardiovascular Disease and is the
Director of the Atherosclerosis Research Group.
Dr. Allen Taylor, M.D., Chief, Cardiology Service, Professor of
Medicine, USUHS Walter Reed Army Medical Center in Washington, D.C.
The role of the Steering Committee is to provide overall supervision of
the trial and ensure that it is being conducted in accordance with the
principles of Good Clinical Practice and FDA regulations. The Steering
Committee will agree on the trial protocol, any protocol amendments and
provide advice to the investigators on all aspects of the trial.
Apolipoprotein A-I (ApoA-I), the main component of high-density
lipoprotein (HDL) represent the body's natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e. transport of
peripheral cholesterol including that of the vessel wall to the liver for
elimination from the body. In multiple human and animal studies
over-expression or repeated infusion of ApoA-I inhibit progression and induce
regression of atherosclerosis in animals and humans.
RVX-208, a novel small molecule drug that facilitates endogenous ApoA-I
production, is positioned as an emerging drug that holds the most promise for
the treatment of atherosclerosis. RVX-208 is designed to increase ApoA-I
production and thereby raise HDL levels thus enhancing HDL functionality to
augment reverse cholesterol transport.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and
other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases, such
as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange
(TSX:RVX). For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Email: Theresa@resverlogix.com;
Donald McCaffrey, President & CEO, Resverlogix Corp., Phone: (403) 254-9252,
Email: Don@resverlogix.com; Website: www.resverlogix.com